Table 1. Clinicopathological characteristics disaggregated by TP53 signature status.

	Total		Mutant type		Wild type
	No. of patients	%	No. of patients	%	No. of patients	%	P*
Samples	174	100	64	37	110	63
Age, years (median)	26–98 (58.0)		37–83 (58.5)		26–98 (57.0)		0.233
pStage
I	85	49	24	39	61	58
IIA	59	34	28	43	31	28
IIB	30	17	12	19	18	16	0.058
ER
Positive	124	71	28	44	96	87
Negative	50	29	36	56	14	13	<0.001
PgR
Positive	95	54	16	25	79	72
Negative	79	46	48	75	31	28	<0.001
HER2
Positive	16	9	12	19	4	4
Negative	158	91	52	81	106	96	0.002
Pathological tumor size, cm
T1	112	64	39	61	73	66
T2	60	35	25	39	35	32
T3	2	1	0	0	2	2	0.374
Node
Positive	55	32	25	39	30	27
Negative	119	68	39	61	80	73	0.149
Grade
1	43	26	3	5	40	38
2	74	44	19	30	55	52
3	51	30	41	65	10	1	<0.001
Adjuvant chemotherapy
+	77	44	42	66	35	35
−	97	56	22	34	75	65	<0.001
Adjuvant Endocrine therapy
+	123	71	25	39	98	89
−	51	29	39	61	12	11	<0.001

Abbreviations: pStage, pathological stage; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor type 2.

P^*: Chi-square test was used for statistical analysis of patients' characteristics except for age.

Kruskal–Wallis test was used for statistical analysis of patients' age.